Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Exemestane|DRUG: Goserelin|DRUG: Carboplatin
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Pfizer